The 3rd Conference on Asian Trends in Prostate Cancer Hormone Therapy.
From its inception in 2001, the Conference on Asian Trends in Prostate Cancer Hormone Therapy has served as an annual forum for Asian urologists to compare data on prostate cancer and to discuss issues regarding the use of hormone therapy. The 3rd conference, held in Tokyo in December 2003, began with participants from China, Indonesia, Japan, Korea, Singapore, and Taiwan presenting QOL data deriving from a survey of patients with prostate cancer. For this purpose, each country translated the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire into its own language. Although the surveys conducted in each country included a heterogeneous cohort of patients and gave very mixed results, the trial of FACT-P in Asian countries seemed propitious and in future may provide insights that could prove beneficial to patients. Day 2 of the conference included 2 discussions, focusing on the most appropriate number of biopsy cores and the implementation of prospective trials involving the collaboration of Asian countries, respectively. In the latter discussion, although a varied assortment of proposals were put forth, the participants generally agreed that any collaborative study must be a prospective outcome study conducted in a relatively short time not exceeding 2-3 years, and that patient registration should be done using the Internet.
Akaza
Hideyuki
H
Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki 305-8576, Japan. akazah@md.tsukuba.ac.jp
Naito
Seiji
S
Chang
Shu-Jen
SJ
Chen
Kuang-Kuo
KK
Cheng
Christopher
C
Choi
Han-Yong
HY
Fujioka
Tomoaki
T
Hinotsu
Shiro
S
Hirao
Yoshihiko
Y
Hong
Sung-Joon
SJ
Kim
Choung-Soo
CS
Kim
Wun-Jae
WJ
Lee
Sang Eun
SE
Murai
Masaru
M
Ogawa
Osamu
O
Rim
Joung-Sik
JS
Soebadi
Doddy M
DM
Song
Jae Mann
JM
Tsukamoto
Taiji
T
Umbas
Rainy
R
Usami
Michiyuki
M
Xia
Shujie
S
Yang
Chi-Rei
CR
Yoon
Jin Han
JH
Zhou
Liqun
L
D000726:Androgen Antagonists / Q000627:therapeutic use*; D000813:Anilides / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001208:Asia; D001706:Biopsy; D003625:Data Collection; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000639:trends; D009570:Nitriles; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000523:psychology / Q000601:surgery; D011788:Quality of Life; D011795:Surveys and Questionnaires; D014105:Tosyl Compounds
D000726:Androgen Antagonists; D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014105:Tosyl Compounds; D007987:Gonadotropin-Releasing Hormone; C053541:bicalutamide